title: Multiple receptor tyrosine kinases promote the in vitro phenotype of metastatic human osteosarcoma cell lines.
abstract: The survival rate for osteosarcoma patients with localized disease is 70% and only 25% for patients with metastases. Therefore, novel therapeutic and prognostic tools are needed. In this study, extensive screening and validation strategies identified Axl, EphB2, FGFR2, IGF-1R and Ret as specific receptor tyrosine kinases (RTKs) that are activated and promote the in vitro phenotype of two genetically different metastatic osteosarcoma cell lines. Initial phosphoproteomic screening identified twelve RTKs that were phosphorylated in 143B and/or LM7 metastatic human osteosarcoma cells. A small interfering RNA (siRNA) screen demonstrated that siRNA pools targeting ten of the twelve RTKS inhibited the in vitro phenotype of one or both cell lines. To validate the results, we individually tested the four siRNA duplexes that comprised each of the effective siRNA pools from the initial screen. The pattern of phenotype inhibition replicated the pattern of mRNA knockdown by the individual duplexes for seven of the ten RTKs, indicating the effects are consistent with on-target silencing. Five of those seven RTKs were further validated using independent approaches including neutralizing antibodies (IGF-1R), antisense-mediated knockdown (EphB2, FGFR2, and Ret) or small molecule inhibitors (Axl), indicating that those specific RTKs promote the in vitro behavior of metastatic osteosarcoma cell lines and are potential therapeutic targets for osteosarcoma. Immunohistochemistry demonstrated that Axl is frequently activated in osteosarcoma patient biopsy samples, further supporting our screening and validation methods to identify RTKs that may be valuable targets for novel therapies for osteosarcoma patients.
authors.affiliation: 1] Department of Orthopaedics, Case Western Reserve University, Cleveland, OH, USA [2] Department of Pathology, Case Western Reserve University, Cleveland, OH, USA.
authors.forename: A N
authors.initials: AN
authors.lastname: Rettew
authors.forename: E D
authors.initials: ED
authors.lastname: Young
authors.forename: D C
authors.initials: DC
authors.lastname: Lev
authors.forename: E S
authors.initials: ES
authors.lastname: Kleinerman
authors.forename: F W
authors.initials: FW
authors.lastname: Abdul-Karim
authors.forename: P J
authors.initials: PJ
authors.lastname: Getty
authors.forename: E M
authors.initials: EM
authors.lastname: Greenfield
references.citation: Mol Cell Biochem. 2009 Jul;327(1-2):257-66
references.pmid: 19229591
references.citation: Pediatr Blood Cancer. 2008 Jun;50(6):1190-7
references.pmid: 18260118
references.citation: Mol Biol Cell. 2007 Oct;18(10):4003-12
references.pmid: 17686994
references.citation: Mod Pathol. 2003 Jan;16(1):66-71
references.pmid: 12527715
references.citation: Cancer Biol Ther. 2010 Nov 15;10(10):1009-18
references.pmid: 20818175
references.citation: Clin Exp Metastasis. 1999;17(6):501-6
references.pmid: 10763916
references.citation: BMC Cancer. 2011 Jul 22;11:309
references.pmid: 21781317
references.citation: Eur J Cancer. 1999 Jul;35(7):1089-93
references.pmid: 10533453
references.citation: J Clin Oncol. 2008 Feb 1;26(4):633-8
references.pmid: 18235123
references.citation: Nat Rev Cancer. 2003 Sep;3(9):685-94
references.pmid: 12951587
references.citation: Lab Invest. 2011 Mar;91(3):392-403
references.pmid: 21060307
references.citation: Neoplasia. 2007 Aug;9(8):678-88
references.pmid: 17786187
references.citation: Cancer Treat Rev. 2006 Oct;32(6):423-36
references.pmid: 16860938
references.citation: Clin Exp Metastasis. 2003;20(7):665-74
references.pmid: 14669798
references.citation: Pathol Int. 1998 Oct;48(10):757-62
references.pmid: 9788258
references.citation: J Natl Cancer Inst. 1992 Jun 17;84(12):966-71
references.pmid: 1321252
references.citation: Annu Rev Biochem. 2000;69:373-98
references.pmid: 10966463
references.citation: Methods Mol Biol. 2000;132:365-86
references.pmid: 10547847
references.citation: Methods Mol Biol. 2012;795:1-34
references.pmid: 21960212
references.citation: Hum Pathol. 2009 Sep;40(9):1244-51
references.pmid: 19368956
references.citation: Cancer Res. 2004 Feb 1;64(3):781-8
references.pmid: 14871799
references.citation: Pediatr Blood Cancer. 2006 May 1;46(5):614-23
references.pmid: 16007579
references.citation: Science. 2006 May 26;312(5777):1175-8
references.pmid: 16728632
references.citation: Cancer Res. 2010 Feb 15;70(4):1544-54
references.pmid: 20145120
references.citation: J Clin Oncol. 2002 Feb 1;20(3):776-90
references.pmid: 11821461
references.citation: Cancer. 2002 Aug 15;95(4):862-9
references.pmid: 12209731
references.citation: Cancer Res. 2012 May 15;72(10):2501-11
references.pmid: 22461510
references.citation: Cancer Res. 1994 May 15;54(10):2803-7
references.pmid: 8168113
references.citation: Pediatr Blood Cancer. 2010 Jul 15;55(1):67-75
references.pmid: 20486173
references.citation: Bone. 2006 Apr;38(4):509-20
references.pmid: 16316790
references.citation: J Natl Cancer Inst. 2010 Jan 20;102(2):107-18
references.pmid: 20068194
references.citation: Cancer Res. 2005 Oct 15;65(20):9226-35
references.pmid: 16230383
references.citation: Mod Pathol. 2006 May;19(5):738-45
references.pmid: 16528367
references.citation: Cytokine Growth Factor Rev. 2004 Dec;15(6):419-33
references.pmid: 15561600
references.citation: Nucleic Acids Res. 2011 Jan;39(Database issue):D945-50
references.pmid: 20952405
references.citation: Nat Rev Cancer. 2010 Mar;10(3):165-80
references.pmid: 20179713
references.citation: Mol Cancer Ther. 2010 Feb;9(2):410-8
references.pmid: 20124453
references.citation: Proteomics. 2008 Nov;8(21):4370-82
references.pmid: 18814326
references.citation: Clin Exp Metastasis. 2005;22(4):319-29
references.pmid: 16170668
references.citation: N Engl J Med. 2005 Jul 14;353(2):172-87
references.pmid: 16014887
references.citation: Clin Orthop Relat Res. 2008 Sep;466(9):2168-75
references.pmid: 18607665
references.citation: RNA. 2006 Jul;12(7):1179-87
references.pmid: 16682560
references.citation: Br J Cancer. 2002 Mar 18;86(6):864-9
references.pmid: 11953816
references.citation: Cancer. 1996 Jan 1;77(1):71-8
references.pmid: 8630943
references.citation: Hum Mol Genet. 2009 Jun 1;18(11):1962-75
references.pmid: 19286668
references.citation: FEBS J. 2011 Oct;278(19):3782-92
references.pmid: 21834878
references.citation: Mol Cancer Ther. 2002 Dec;1(14):1349-53
references.pmid: 12516969
references.citation: J Surg Oncol. 1998 Sep;69(1):21-7
references.pmid: 9762887
references.citation: Mol Cancer Ther. 2010 Sep;9(9):2593-604
references.pmid: 20716637
references.citation: Oncogene. 1995 Feb 16;10(4):739-49
references.pmid: 7862451
references.citation: BMC Cancer. 2011 May 29;11:209
references.pmid: 21619704
references.citation: Int J Cancer. 1999 Feb 9;80(4):581-8
references.pmid: 9935160
references.citation: Curr Oncol Rep. 2009 Jul;11(4):307-13
references.pmid: 19508836
references.citation: Histopathology. 2010 Dec;57(6):836-50
references.pmid: 21166698
references.citation: J Clin Endocrinol Metab. 2010 Nov;95(11):E342-6
references.pmid: 20702524
references.citation: J Clin Oncol. 1999 Sep;17(9):2781-8
references.pmid: 10561353
references.citation: J Am Acad Orthop Surg. 2009 Aug;17(8):515-27
references.pmid: 19652033
references.citation: Int J Oncol. 2000 Aug;17(2):291-5
references.pmid: 10891538
references.citation: Clin Cancer Res. 2011 Feb 1;17(3):611-9
references.pmid: 21127194
references.citation: Clin Orthop Relat Res. 2006 Jul;448:193-8
references.pmid: 16826116
references.citation: Mol Cancer Ther. 2010 Jun;9(6):1697-708
references.pmid: 20530713
references.citation: Cancer Invest. 2001;19(3):292-315
references.pmid: 11338887
references.citation: Cancer Sci. 2009 Dec;100(12):2268-74
references.pmid: 19725836
references.citation: Int J Cancer. 2006 Mar 1;118(5):1165-72
references.pmid: 16152617